论文部分内容阅读
近日,一项发表在国际杂志EbioMedicine上的研究报告中,来自弗莱堡大学等多个机构的研究人员通过研究鉴别出了一种癌症疗法的新型靶点,文章中,研究者发现,名为RIOK1的酶类能够同在肿瘤中经常发生突变的RAS蛋白互相协作来促进肿瘤生长以及癌症的转移;继发性肿瘤往往能够通过原发性肿瘤扩散,如果其没有被及时移除的话就会引发很多癌症患者死亡;研究者认为,他们有望利用一种特殊的抑制剂来阻断酶类RIOK1的活性,从而减缓癌症的进展。
Recently, a study published in the international magazine EbioMedicine, researchers from various institutions such as the University of Freiburg identified a new target for cancer therapy through research. In the article, the researchers found that the name of RIOK1 enzymes are capable of cooperating with RAS proteins, which frequently mutate in tumors, to promote tumor growth and cancer metastasis; secondary tumors are often able to spread through the primary tumor and cause it to erupt if it is not removed promptly Many cancer sufferers die; researchers believe they are expected to use a specific inhibitor to block the activity of the enzyme RIOK1, thereby slowing the progression of the cancer.